drugset / Trial / NCT05759208

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

NCT05759208 ↗

Phase 2 Completed 240 enrolled Okyo Pharma Ltd ORA, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to compare the safety and efficacy of OK-101 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

Timeline

Start
2023-04-28
Primary completion
2023-12-15
Completion
2023-12-15

Outcome

Missed primary endpoint

release “While we didn’t meet the original primary endpoints, the totality of the data support advancing forward with a new study design” okyopharma.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject OK-101 Peptide 0.05 % Other
Subject OK-101 Peptide 0.1 % Other

Indications